Psychedelic-Assisted Psychotherapy

State of the evidence

The evidence is strong for the efficacy of psilocybin in treating Major Depressive Disorder (MDD) and treatment-resistant depression 1,2,5, and MDMA-assisted therapy for severe PTSD 3,9,10. Psilocybin also shows significant efficacy in reducing heavy drinking days for alcohol use disorder 8. These effects are associated with rapid symptom reduction 1,5 and changes in brain network functional connectivity 7. However, long-term durability varies, and the transition to clinical practice is limited by a lack of standardized models 8,10.

Key findings

• Psilocybin produces rapid and clinically significant antidepressant effects in patients with MDD and treatment-resistant depression 1,2,5. 1 2 5
• MDMA-assisted therapy significantly reduces PTSD symptom severity and functional impairment compared to placebo 3,9. 3 9
• Psilocybin-assisted psychotherapy significantly reduces the percentage of heavy drinking days and drinking-related problems in patients with alcohol use disorder 8. 8
• Therapeutic effects are linked to post-treatment decreases in cerebral blood flow and changes in resting-state functional connectivity 7. 7
• MDMA-assisted therapy shows a large effect size for PTSD, potentially surpassing the efficacy of standard FDA-approved pharmacotherapies like paroxetine and sertraline 10. 10

Where the evidence disagrees

• While psilocybin shows rapid onset 1, the long-term durability of these effects across different patient populations remains a subject of ongoing study 6.
• The efficacy of psilocybin versus standard SSRIs (like escitalopram) requires further direct comparative data to establish superiority 4.

Open opportunities

What the research supports that no idea in the catalog takes yet.

• Alcohol Use Disorder Relapse Prevention Monitoring System

  Evidence shows psilocybin reduces heavy drinking days 8, but a tool to monitor and trigger interventions during the 12-week psychotherapy window is missing.

• Comparative Efficacy Dashboard for PTSD Pharmacotherapy

  Since MDMA-AT may outperform paroxetine/sertraline 10, a clinical decision tool comparing these modalities would assist in patient triaging.

• fMRI-Based Treatment Response Predictor for TRD

  P6 identifies specific brain network changes; a tool that maps baseline connectivity to predicted psilocybin response could optimize patient selection.

References

1. 1.Effects of Psilocybin-Assisted Therapy on Major Depressive DisorderAlan K. Davis, Frederick Streeter Barrett, Darrick G. May et al. · 2020 · 1319 citations
2. 2.Single-Dose Psilocybin for a Treatment-Resistant Episode of Major DepressionGuy M. Goodwin, Scott T. Aaronson, Oscar Alvarez et al. · 2022 · 1098 citations
3. 3.MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyJennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. · 2021 · 968 citations
4. 4.Trial of Psilocybin versus Escitalopram for DepressionRobin Carhart‐Harris, Bruna Giribaldi, Rosalind Watts et al. · 2021 · 1378 citations
5. 5.Single-Dose Psilocybin Treatment for Major Depressive DisorderCharles L. Raison, Gerard Sanacora, Joshua Woolley et al. · 2023 · 496 citations
6. 6.Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-upNatalie Gukasyan, Alan K. Davis, Frederick S. Barrett et al. · 2022 · 419 citations
7. 7.Psilocybin for treatment-resistant depression: fMRI-measured brain mechanismsRobin Carhart‐Harris, Leor Roseman, Mark Bolstridge et al. · 2017 · 605 citations
8. 8.Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use DisorderMichael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. · 2022 · 670 citations
9. 9.MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trialJennifer Mitchell, Marcela Ot’alora G., Bessel van der Kolk et al. · 2023 · 428 citations
10. 10.Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and SertralineAllison A. Feduccia, Lisa Jerome, Berra Yazar‐Klosinski et al. · 2019 · 173 citations